TKNO Healthcare

Alpha Teknova, Inc.

$7.34+4.71%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 394.1M USD
Enterprise value: 375.9M USD
Full-time employees: 158

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #874 of 1,157 healthcare companies (bottom 25%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 91% from December 2022 to August 2026.
Alpha Teknova had 91% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Alpha Teknova had 91% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Alpha Teknova looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Alpha Teknova reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

37/ 100

Oct 5 37 → Nov 4 37

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-4.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-2.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-1.9%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield15.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

52/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 4.5%

Why

Helped by:

▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth3.7%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.26Sector median: 0.0584 · MAD: 0.0840

Revenue growth12.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.63Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

22/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 2.8 points to -36.2%

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-36.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.55Sector median: 0.0706 · MAD: 0.1217

Return on assets-17.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.57Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-17.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.25Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin34.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-26.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Helped by:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.73

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.31Sector median: 0.6250 · MAD: 0.3380

Current ratio4.49×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.37Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.21×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.05Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Alpha Teknova

Is Alpha Teknova getting weaker?: Its latest SEC filing (Aug 6, 2026) got stronger: operating margin rose 2.8 points to -36.2%. Its overall score is unchanged at 37/100 since Oct 28, 2026.
How is Alpha Teknova valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -4.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.3% vs peers 1.5% (weaker than 100% of peers).
Is Alpha Teknova growing?: At about the same pace as its peers. Growth scores 52/100 against 1,393 healthcare peers. Revenue growth 12.3% vs a peer median of 6.1% (stronger than 66% of peers).Revenue growth 12.3% vs peers 6.1% (stronger than 66% of peers).
How profitable is Alpha Teknova?: Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Operating margin -36.2% vs a peer median of 7.1% (weaker than 82% of peers).Operating margin -36.2% vs peers 7.1% (weaker than 82% of peers).
How risky is Alpha Teknova?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.49× vs a peer median of 2.59× (stronger than 69% of peers).Current ratio 4.49× vs peers 2.59× (stronger than 69% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 2.8 points to -36.2%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	41.8M USD	43.7M USD	+4.5%
Net income (12 months)	−17.2M USD	−16.8M USD	−2.3%
Operating margin	-39.0%	-36.2%	+2.8 pts
Free cash flow (12 months)	−9.1M USD	−7.4M USD	−18.9%
Debt	13.2M USD	13.2M USD	+0.4%
Cash	4.3M USD	6.0M USD	+39.4%
Shares outstanding	53.6M	53.7M	+0.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	47.8%	42.2%	28.1%	19.2%	33.2%	▲ 14 pts
Operating margin	-32.5%	-119.9%	-96.9%	-69.3%	-41.9%	▲ 27 pts
Net margin	-26.6%	-114.6%	-100.3%	-70.9%	-42.6%	▲ 28 pts
Return on assets (ROA)	-5.9%	-31.2%	-28.6%	-22.5%	-16.7%	▲ 5.9 pts
Return on equity (ROE)	-6.8%	-47.5%	-40.9%	-32.5%	-25.1%	▲ 7.4 pts
Free cash flow margin	-78.5%	-134.1%	-72.9%	-35.8%	-24.2%	▲ 12 pts
Current ratio	13.07×	5.62×	5.14×	3.82×	4.58×	▲ 20%
Quick ratio	12.37×	4.50×	3.84×	3.21×	3.64×	▲ 14%
Debt to equity	0.08×	0.22×	0.15×	0.11×	0.19×	▲ 66%

TKNO price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #874 of 1,157 healthcare companies (bottom 25%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 91% from December 2022 to August 2026.

Alpha Teknova had 91% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Alpha Teknova had 91% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Alpha Teknova looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Alpha Teknova reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Alpha Teknova

Is Alpha Teknova getting weaker?

Its latest SEC filing (Aug 6, 2026) got stronger: operating margin rose 2.8 points to -36.2%. Its overall score is unchanged at 37/100 since Oct 28, 2026.

How is Alpha Teknova valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -4.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.3% vs peers 1.5% (weaker than 100% of peers).

Is Alpha Teknova growing?

At about the same pace as its peers. Growth scores 52/100 against 1,393 healthcare peers. Revenue growth 12.3% vs a peer median of 6.1% (stronger than 66% of peers).Revenue growth 12.3% vs peers 6.1% (stronger than 66% of peers).

How profitable is Alpha Teknova?

Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Operating margin -36.2% vs a peer median of 7.1% (weaker than 82% of peers).Operating margin -36.2% vs peers 7.1% (weaker than 82% of peers).

How risky is Alpha Teknova?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.49× vs a peer median of 2.59× (stronger than 69% of peers).Current ratio 4.49× vs peers 2.59× (stronger than 69% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

41.8M USD

43.7M USD

+4.5%

Net income (12 months)

−17.2M USD

−16.8M USD

−2.3%

Operating margin

-39.0%

-36.2%

+2.8 pts

Free cash flow (12 months)

−9.1M USD

−7.4M USD

−18.9%

Debt

13.2M USD

13.2M USD

+0.4%

Cash

4.3M USD

6.0M USD

+39.4%

Shares outstanding

53.6M

53.7M

+0.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

47.8%

42.2%

28.1%

19.2%

33.2%

▲ 14 pts

Operating margin

-32.5%

-119.9%

-96.9%

-69.3%

-41.9%

▲ 27 pts

Net margin

-26.6%

-114.6%

-100.3%

-70.9%

-42.6%

▲ 28 pts

Return on assets (ROA)

-5.9%

-31.2%

-28.6%

-22.5%

-16.7%

▲ 5.9 pts

Return on equity (ROE)

-6.8%

-47.5%

-40.9%

-32.5%

-25.1%

▲ 7.4 pts

Free cash flow margin

-78.5%

-134.1%

-72.9%

-35.8%

-24.2%

▲ 12 pts

Current ratio

13.07×

5.62×

5.14×

3.82×

4.58×

▲ 20%

Quick ratio

12.37×

4.50×

3.84×

3.21×

3.64×

▲ 14%

Debt to equity

0.08×

0.22×

0.15×

0.11×

0.19×

▲ 66%